Overall Status

Not yet recruiting (2)

Completed (1)

Recruiting (1)

Phase

early phase 1 (1)

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Affimed GmbH (1)

Applied Biology, Inc. (1)

Arbutus Biopharma Corporation (1)

Artiva Biotherapeutics, Inc. (1)

Collaborator

Artiva Biotherapeutics, Inc. (1)

Intervention

ab-101 (4)

cyclophosphamide (2)

fludarabine (2)

interleukin-2 (2)

placebo (2)

afm13 (1)

nucleos(t)ide analogue (1)

rituximab (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Industry (4)

Study Type

Interventional (4)

ab-101

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Chronic Hepatitis b Trial in Auckland (AB-101, Placebo, Nucleos(t)ide Analogue)

Not yet recruiting

Chronic Hepatitis b

AB-101
+2 more

Auckland, New Zealand

New Zealand Clinical Research Auckland

Jul 26, 2023

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting

Relapsed or Refractory Hodgkin Lymphoma
Peripheral T Cell Lymphoma

AFM13
+4 more

(no location specified)

May 30, 2023

Non Hodgkin Lymphoma Trial in United States (AB-101, Rituximab, Interleukin-2)

Recruiting

Non Hodgkin Lymphoma

AB-101
+4 more

Birmingham, Alabama
+7 more

Dec 22, 2021

Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological Trial in Newport Beach (AB-101, Placebo)

Completed

Has Results

Sexual Dysfunction
+6 more

AB-101
Placebo

Newport Beach, California

Southern CA Center for Sexual Health and Survivorship Medicine

Mar 3, 2020